Thailand aims to end its AIDS epidemic by 2030, and key strategies to effect this include an increase in HIV testing coverage to 90% for key populations (i.e. men who have sex with men, sex workers, people who inject drugs and partners of people living with HIV) and antiretroviral treatment (ART) initiation for all, regardless of CD4 cell count. Thailand is now focusing its national HIV strategic plan on the recruit-test-treat-retain cascade. In order to recruit more key populations into HIV testing, offer immediate ART and retain both HIV-negative people for regular HIV testing and HIV-positive people for continued ART service, effective communication to the community about the clear benefits of early HIV diagnosis and early ART has become more important than ever.

Community participation in HIV research in Thailand started more than a decade ago. Widespread concerns over people in the community being used and treated unfairly like guinea pigs in HIV research studies, HIV vaccine trials in particular, have driven strong demands from the community to be effectively engaged in the entire research life-cycle from study design to result dissemination. Participation occurred naturally with the demand from the community to understand more about the research to be conducted and to share their views and concerns with the researchers. Meetings, forums and demonstrations have been used for that purpose until the community advisory board (CAB) has become widely accepted locally and globally as an official way of obtaining community participation when doing research. CABs have been established in many research settings in Thailand as protocol-specific, institution-based or key population-based CABs. In general, HIV prevention research causes more concern to the community than therapeutic research. Common concerns include sufficient provision of comprehensive HIV prevention packages to participants in HIV prevention trials, and post-trial access to HIV prevention products or procedures for the participants and the country as a whole. Good participatory practice (GPP) guidelines for biomedical HIV prevention trials have recently been introduced as systematic guidance on how to engage stakeholders effectively in the development, planning, implementation and conclusion of a trial, including dissemination of trial results [@jve9-bib-0001]. GPP has also been adapted for use in other settings outside HIV prevention research [@jve9-bib-0002].

GPP proposes the use of as many formal and informal stakeholder advisory mechanisms as possible to acquire community participation in the research. These mechanisms include stakeholder meetings, local events, ongoing dialogue with community-based organisations (CBO), focus group discussions, talk radio/TV shows, CABs, and non-governmental organisation (NGO) advisory and participant groups. The GPP has been used actively in many completed and ongoing HIV vaccine, pre-exposure prophylaxis and other HIV prevention studies in Thailand [@jve9-bib-0003]. According to GPP, stakeholders include trial participants, community stakeholders (CBOs, participants' family, friends, schools, colleagues, peers, trial site staff, local religious institutions, traditional leaders, community advisory boards and local health service providers), broader stakeholders (NGOs, local policy makers, local media and medical professionals), as well as national (parliamentarians, Ministry of Health, media, regulatory bodies, ethical review committees, funders, sponsors) and international stakeholders (international NGOs, international organisations, networks, sponsors and funders).

For HIV cure research in particular, media attention has become both a strength and a weakness for community participation. Currently, ART can reduce HIV viral burden and infectiousness although it does require strict adherence to daily medications. What could an HIV cure offer beyond this? In the medical community, a cure could be HIV remission (living with HIV without HIV RNA detected in the blood), or HIV eradication (no HIV in the body and completely HIV negative). However, it is not well understood what HIV cure means to those within the community who are at risk of HIV but have never been tested or still test negative, to those who are currently living with HIV with and without ART, and to those who are diagnosed early or late. The word 'cure' certainly has different meanings for different people: from living with HIV without the risk of transmitting the virus to others, to living without any traces of HIV in the body [@jve9-bib-0004].

Recent news regarding a possible HIV cure case in Thailand [@jve9-bib-0005] demonstrates an example of large variations in reactions among the Thai community, from very cautious to ready to believe. Alongside real HIV cure news, the Thai community has experienced fake HIV cure news before [@jve9-bib-0006]. Without a good communication and issue management plan that follows the GPP [@jve9-bib-0001], these news stories have the potential to send out wrong or pre--emptive messages to those people living with HIV on ART who may risk stopping their ART to see whether their HIV has been cured. On the other hand, media attention could be used as one of the most robust tools to educate and communicate correct messages around HIV cure to the community.

Basic questions around HIV may again be coming back in this era of cure research. What is HIV? What does HIV do to you? How does HIV medicine work? Basic concerns around being involved in research studies have also become more specific and in a manner that is different from those asked to be involved in HIV prevention or other HIV treatment studies. Who is participating in such HIV cure research? What are the risks of participating, and what will one get out of this research? Asking people with acute HIV infection with their uniquely low reservoir to participate in HIV cure research using an intervention without ample data on effectiveness and safety, means that he/she will risk reseeding the reservoir and probably losing options for future trials with better interventions. People may want to wait for a better marker of viraemic control or a more effective intervention to be available before joining such a study. In addition, health service providers and their clients are now asking how soon after an exposure should one test for HIV. This is a question around the window period, which differs from one setting to another depending on the HIV testing methods. Knowing that diagnosing HIV within the first 2--4 weeks of acquiring HIV infection might give a better chance of a future cure, may well affect willingness to test initially as well as to test quickly after any further potential exposure. The community is also demanding that the benefits and risks of early ART be communicated clearly to them.

How should researchers promote community participation in HIV cure research? Simply ask this question to the children and adults around you, and the answers may include invitations to visit homes for further discussions, make booklets, create videos and post on YouTube, do public presentations, do surveys, or hold public meetings where people can come and share ideas. All these fit well with what is recommended in GPP but the question is: are we doing enough?

In Thailand, as one of the countries with the most advanced research studies in HIV cure, owing to the successful establishment of the SEARCH 010/RV254 study at the Thai Red Cross AIDS Research Centre in Bangkok [@jve9-bib-0007] and the RV217 study at the ECHO Center in Pattaya, community participation in HIV research could be strongly promoted in the following ways. First, the community should be updated on the steps towards HIV cure, from identifying HIV at its earliest stage, treating as early as possible after HIV diagnosis in order to limit HIV replication and reservoir size, identifying interventions to enhance the body\'s immune system and/or killing residual HIV, and interrupting ART. Secondly, the community should be encouraged to voice their concerns and advise on how we should move together through the next stages, not only at a research setting level but at a national level. HIV cure research should not be seen as a separate issue from the recruit-test-treat-retain cascade, but rather as an ideal subsection in which the complete cascade can be demonstrated. Finally, looking into the future, all stakeholders should work together using the lessons already learned to maintain and then increase the momentum for early testing and early treatment. Community participation through CAB has been an important foundation but researchers and community stakeholders must not be complacent and now need to build on that input and make use of current and innovative consultation methods as outlined in GPP to further improve communication.
